The struggling biotech company is looking to break into the lucrative hepatitis C market with the promise of an easier ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
The ADA recommended doctors avoid prescribing unapproved, off-brand versions of drugs like Wegovy, wading into a dispute that ...
The AIntibody Challenge seeks to rigorously test AI-driven antibody design and in silico predictions against experimentally validated datasets. Focusing on antibodies targeting the RBD ...
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to ...
Using tumor-treating fields alongside chemotherapy improved patient survival, Novocure said. Elsewhere, Cytokinetics got a ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue ...
The company reached a deal to divest its third biosimilar this year, selling a copycat version of Amgen’s Neulasta for up to ...
A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the ...